Background: Diabetes is the leading cause of morbidity and mortality, with a number currently diagnosed as high as 371 million. Plant-based therapy could be an ideal choice because of fewer side-effects and wider acceptability. Hence, the antihyperglycemic potential of Aerva lanata, a herb prescribed for diabetes in Ayurveda was evaluated to elucidate its possible mechanism of action.
Methods: High performance liquid chromatography analysis was used for the characterization of 70% ethanolic (aqueous leaf extract [ALE]) and ethyl acetate (AEA) extracts. Further, they were evaluated for their antioxidant, inhibition of alpha glucosidase, protein glycation dipeptidyl peptidase IV (DPP IV), protein tyrosine phosphatase 1B (PTP1B) and stimulation of glucose uptake and glitazone like property (adipogenic potential) using in vitro models. The promising alpha glucosidase inhibitory potential of ALE was further evaluated in normal and streptozotocin (STZ) diabetic rats.
Results: ALE inhibited yeast (IC50 - 81.76 μg/mL) and rat intestinal alpha glucosidase (IC50 - 108.7 μg/mL), protein glycation, DPP IV enzyme (IC50 - 118.62 μg/mL) and PTP1B (IC50 - 94.66 μg/mL). ALE stimulated maximal adipogenesis at 50 μg/mL and enhanced insulin mediated glucose uptake (threefold of basal) at 100 μg/mL in L6 myotubes. ALE (500 mg/kg b.w.) showed a significant antihyperglycemic activity in sucrose loaded STZ normal (15.57%) and diabetic (18.44%) rats. HPLC analysis of ALE revealed the presence of bioactives like alpha amyrin, betulin and beta sitosterol.
Conclusions: Alpha glucosidase inhibition, antiglycation, and adipogenic potential significantly contribute to the antidiabetic property of Aerva lanata. In addition, insulin sensitization and antioxidant potential also enhance its therapeutic potential.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/1753-0407.12216 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!